stockrow
Saturday 7 November 2026
Export DWTX’s income statement to Excel — free account
Dogwood Therapeutics, Inc
DWTX Healthcare Biotechnology
- EPS
- +82.9%
- Free cash flow
- +10.3%
Quarter to June 2026, against a year earlier
1.32
0.28
+26.92%
Follow DWTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 3 | 3 | 3 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | (2) | (2) | (10) | (16) | (12) | (5) | (12) | (34) | (38) | +48.7% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (2) | (2) | (10) | (16) | (12) | (5) | (12) | (34) | (36) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.26) | (12.80) | (52.50) | (48.00) | (27.75) | (7.00) | (12.52) | (7.13) | (8.95) | +60.5% | ||||||
| Cash flow | — | — | (0.15) | (10.82) | (19.76) | (47.09) | (25.90) | (6.49) | (8.55) | (3.14) | (0.44) | +54.0% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.15) | (10.82) | (19.76) | (47.09) | (25.90) | (6.49) | (8.55) | (3.14) | (0.44) | +54.0% | ||||||
| Book value | — | — | (1.83) | (25.96) | 151.91 | 43.52 | 16.55 | 5.07 | 62.53 | 15.05 | 2.00 | n/m | ||||||
| Shares, m | — | — | 8 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 19 | (7.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (1) | (2) | (4) | (16) | (11) | (5) | (9) | (16) | (15) | +43.2% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | (1) | (2) | (4) | (16) | (11) | (5) | (9) | (16) | (15) | +43.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | (1) | (1) | 30 | 15 | 7 | 4 | 13 | 5 | 8 | n/m | |||||
| Net debt | — | — | 0 | 3 | (30) | (14) | (7) | (3) | 1 | (7) | (10) | +115.7% | ||||||
| Shareholders’ equity | — | — | (15) | (5) | 30 | 15 | 7 | 4 | 64 | 75 | 68 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (6,414.57) | (1,295.76) | (65.10) | (67.56) | (101.45) | (84.50) | (26.13) | (38.50) | (40.68) | +6,376.1 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | (4,297.85) | (1,983.28) | (2,604.76) | (694.76) | (11.79) | (25.57) | (41.22) | (25.6) pt | ||||||
| ROE | — | — | 12.90 | 24.54 | (83.03) | (71.83) | (112.22) | (95.14) | 407.25 | (109.66) | (143.45) | (122.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 3 | 5 | 4 | 4 | 12 | 8 | — | +21.7% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Dogwood Therapeutics, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GANX Gain Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SGMOQ Sangamo Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | −77.60% (below 0%: shrinking) | n/m | +26.21% (above 0%: growing) | 100.00% | (2,215.40%) | Compare |
| LONA LeonaBio, Inc. | $40.9M | — (loss-making) | — | — | n/m | −142.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ATNM Actinium Pharmaceuticals, Inc. | $40.9M | 3.9× | 8.4× | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| HYPD Hyperion DeFi, Inc. | $39.8M | — (loss-making) | 0.5× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| DWTX Dogwood Therapeutics, Inc | $39.8M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | |
| EXOZ eXoZymes Inc. | $38.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | Compare |
| IBO Impact Biomedical Inc. | $38.0M | — (loss-making) | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | Compare |
| ELTX Elicio Therapeutics, Inc. | $37.9M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $40.3M | — | — | −13.74% | — | +8.50% | 66.67% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.34m | 2.62m | 17.32 |
| 2024 | 881.22k | 751.88k | 28.94 |
Ownership
Directors and executive officers, together
0.30%
Sealbond Limited
65.30%
Conjoint, Inc.
8.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement